Copyright
©The Author(s) 2022.
World J Diabetes. Dec 15, 2022; 13(12): 1154-1167
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1154
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1154
Diabetic patients without baseline albuminuria, n = 45 | Diabetic patients with baseline albuminuria, n = 20 | P value | |
Age (yr), mean (SD) | 58.7 (9.2) | 62.2 (9.0) | 0.161 |
Median (IQR) | 60.0 (50.5-65.0) | 63.0 (56.5-68.8) | |
Sex, female, n (%) | 21 (46.7) | 11 (55.0) | 0.602 |
Population group, n (%) | 0.772 | ||
Jews | 13 (28.9) | 7 (35.0) | |
Arabs | 32 (71.1) | 13 (65.0) | |
BMI (kg/m2), mean (SD) | 31.6 (4.5) | 33.2 (4.6) | 0.191 |
Median (IQR) | 30.9 (28.6-33.7) | 32.3 (29.7-35.9) | |
Diabetes duration (yr), median (IQR) | 10.0 (5.5-14.0) | 11.0 (5.3-17.0) | 0.251 |
eGFR (mL/min/1.73 m2 body surface area) at baseline, median (IQR) | 90.5 (77.8-99.5) | 95.3 (69.6-101.1) | 0.903 |
HbA1c (%), median (IQR) | 7.2 (6.6-8.4) | 8.9 (7.3-10.4) | 0.023 |
Metformin, n (%) | 41 (91.1) | 15 (75) | 0.124 |
DPP-4 inhibitors, n (%) | 15 (33.3) | 3 (15) | 0.152 |
Sulfonylurea, n (%) | 5 (11.1) | 2 (10) | 1.004 |
SGLT2 inhibitors, n (%) | 15 (33.3) | 3 (15) | 0.152 |
GLP-1 agonists, n (%) | 8 (17.8) | 4 (20) | 1.004 |
Basal insulin, n (%) | 8 (17.8) | 10 (50) | 0.0152 |
Prandial insulin, n (%) | 2 (4.4) | 4 (20) | 0.0674 |
Current smoking, n (%) | 2 (4.4) | 2 (10) | 0.584 |
Retinopathy, n (%) | 4 (12.9) | 3 (20) | 0.674 |
NLRmax, median (IQR) | 6.2 (2.5-9.4) | 6.7 (2.6-18.0) | 0.483 |
CRP (mg/L) at admission, median (IQR) | 90.4 (10.9-153.6) | 43.9 (12.5-106.8) | 0.333 |
CRPmax (mg/L) at hospitalization, median (IQR) | 92.8 (11.4-171.3) | 61.0 (12.5-157.3) | 0.603 |
eGFR (mL/min/1.73 m2 body surface area) at hospitalization, median (IQR) | 90.3 (77.0-98.4) | 94.3 (67.8-101) | 0.763 |
Albumin, median (IQR) | 3.6 (3.3-4.0) | 3.6 (3.1-3.9) | 0.251 |
- Citation: Bashkin A, Shehadeh M, Shbita L, Namoura K, Haiek R, Kuyantseva E, Boulos Y, Yakir O, Kruzel-Davila E. Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia. World J Diabetes 2022; 13(12): 1154-1167
- URL: https://www.wjgnet.com/1948-9358/full/v13/i12/1154.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i12.1154